These susceptibility studies are important to inform lead optimisation and support further drug development.

High-throughput screening identified compound 1 as a potent P2X(7) receptor antagonist suitable for lead optimisation.

There is a need for high-quality screening collections that maximise hit rate and minimise the time taken in lead optimisation to derive a candidate drug.